DNLI
Denali Therapeutics Inc
NASDAQ: DNLI · HEALTHCARE · BIOTECHNOLOGY
$18.60
-7.28% today
Updated 2026-04-29
Market cap
$2.95B
P/E ratio
—
P/S ratio
3,643.65x
EPS (TTM)
$-2.97
Dividend yield
—
52W range
$13 – $24
Volume
1.7M
Denali Therapeutics Inc (DNLI) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-15.05M | $-72.36M | $-76.64M | $50.12M | $-151.58M | $416.15M | $-211.39M | $-244.72M | $-357.99M | $-347.69M | $-412.60M |
| Capital expenditures | $3.06M | $6.13M | $2.88M | $3.39M | $17.92M | $3.10M | $8.50M | $17.83M | $12.94M | $15.91M | $9.50M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $479000.00 | $2.95M | $4.41M | $18.79M | $38.38M | $50.35M | $85.25M | $99.85M | $108.10M | $102.88M | $99.63M |
| Free cash flow | $-18.11M | $-78.49M | $-79.51M | $46.72M | $-169.50M | $413.06M | $-219.89M | $-262.55M | $-370.93M | $-363.61M | $-422.10M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $-140.29M | $2.33M | $427.69M | $-213.67M | — | — | — | — |